STOCK TITAN

Gritstone Bio Inc - GRTS STOCK NEWS

Welcome to our dedicated news page for Gritstone Bio (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gritstone Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gritstone Bio's position in the market.

Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces participation in upcoming investor and scientific conferences to showcase its innovative personalized cancer vaccines. The events will feature presentations and panels discussing clinical trial results and advancements in cancer vaccine technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
conferences
-
Rhea-AI Summary
Gritstone Bio, Inc. updates its EDGE platform at AACR Annual Meeting, showcasing improved prediction accuracy for HLA Class I and II epitopes. EDGE, combined with vaccine vectors, shows potential in identifying neoantigens for robust immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
none
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced a $32.5 million public offering of common stock and warrants, aiming to raise capital for its vaccine development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.94%
Tags
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) initiates a public offering of common stock and warrants underwritten by TD Cowen and Evercore ISI. The offering, subject to market conditions, aims to raise capital for the development of potent vaccines. The company plans to offer shares, pre-funded warrants, and common warrants, with details available on the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.94%
Tags
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces positive preliminary data from Phase 2 study of GRANITE, a personalized neoantigen cancer vaccine, in metastatic colorectal cancer patients. Early PFS trends show benefit for GRANITE recipients, with a high-risk group showing a 48% relative risk reduction in progression or death. Mature PFS data expected in Q3 2024 and overall survival data in 1H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.94%
Tags
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) reported financial results for Q4 2023, highlighting key developments in their oncology and infectious disease programs. The company is expecting preliminary data from the Phase 2 study of their personalized cancer vaccine, GRANITE, in 1Q 2024. They are also preparing to launch a Phase 2b study for their COVID-19 vaccine in Fall 2024. Gritstone's cash position stood at $86.9 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces a 40% reduction in workforce due to delayed funding for the CORAL Phase 2b study. CEO Andrew Allen expresses gratitude to departing employees while emphasizing commitment to ongoing programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.86%
Tags
none
-
Rhea-AI Summary
Gritstone bio, Inc. (GRTS) announces participation in key investor and scientific conferences to discuss breakthroughs in vaccine pipeline and leveraging AI for immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) is adjusting the timeline for the Phase 2b trial of its next-generation COVID-19 vaccine to Fall 2024 to incorporate fully GMP-grade raw materials, enhancing regulatory value and study interpretability. The company aims to address the latest seasonal variant and express gratitude to FDA and BARDA for their support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced the granting of nonqualified stock options to six employees to purchase 147,000 shares of its common stock. The options have an exercise price of $2.26 and will vest over a four-year period, subject to the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
Gritstone Bio Inc

Nasdaq:GRTS

GRTS Rankings

GRTS Stock Data

90.43M
89.91M
2.48%
43.6%
8.99%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Emeryville

About GRTS

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.